

**REMARKS**

The claims pending in the above-identified application following entry of the foregoing amendments will be claims 11-27. Original claims 1-10 have been cancelled.

Claims directed to ophthalmic compositions containing moxifloxacin have been allowed in parent application Serial No. 10/200,868. The new claims submitted above are directed to the use of moxifloxacin to treat ophthalmic infections. As utilized in these claims, the term "treating" is intended to have its common, ordinary meaning, which includes both active and prophylactic treatment of a disease or disorder [see Dorland's Illustrated Medical Dictionary, Twenty-sixth Edition, pages 1388 and 1389 (1981); copy attached].

**Respectfully submitted,  
ALCON RESEARCH, LTD.**

November 17, 2003  
Date

By: Gregg C. Brown  
Gregg C. Brown  
Registration No. 30,613  
Phone No. (817) 551-8663

Address for Correspondence:  
Gregg C. Brown  
Alcon Research, Ltd.  
6201 South Freeway, Mail Code Q-148  
Fort Worth, Texas 76134-2099  
Phone: (817) 551-8663

Attorney Docket No.: 1732 US F2